ReiThera has inked a comprehensive Master Service Agreement (MSA) with SillaJen, which establishes ReiThera as the manufacturing partner for SillaJen’s anticancer virus platform, the SJ-600 series.

Under this agreement, ReiThera will leverage its expertise to conduct advanced development and GMP production of the SJ-600 series, transforming it into a clinical-ready drug capable of entering trials.

As a global Contract Development and Manufacturing Organization (CDMO) based in Italy, ReiThera brings decades of experience in developing and producing antinfective and cancer vaccines, as well as gene therapies. Its deep expertise in producing viruses from the Vaccinia lineage—the foundational virus for the SJ-600 series—makes it the ideal partner for this project.

The SJ-600 series represents a breakthrough in anticancer virus technology. Developed collaboratively by the SillaJen Research Institute and Professor Lee’s team at Seoul National University College of Medicine, it introduces next-generation features that enable repeated administration by avoiding neutralization reactions. Additionally, the platform enhances intravenous delivery by expressing the complement regulatory protein ‘CD55’ on the surface of the virus, significantly improving therapeutic potential.

“Through collaboration with ReiThera, which has international vaccine development experience and the latest facilities, we are now able to promote standardized mass production of the SJ-600 series,” said Sillajen Chief Executive Officer, Jang Dong-taek. “This indicates that we have entered a further stage for licensing out the SJ-600 series.”

“We are thrilled to collaborate with Sillajen on the development and manufacturing of their innovative SJ-600 series,” said Stefano Colloca, CEO of Reithera. “At ReiThera, we pride ourselves on leveraging our extensive experience with virus platforms, State of the Art facilities, and advanced expertise to support groundbreaking therapeutic solutions. This partnership underscores our commitment to driving forward next-generation technologies that have the potential to transform cancer treatment and improve patient outcomes globally.”